Izervay Application Scope

Izervay is a complement C5 protein inhibitor containing avacincaptad pegol, targeting C5 to reduce complement system activity and potentially slow the progression of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Izervay Characteristics

Ingredients:
- Active ingredient: avacincaptad pegol.
Properties:
- Inhibits complement C5 protein, reducing complement system activity to slow GA progression.
Specification:
- 2 mg (0.1 mL of 20 mg/mL solution) in single-dose vials.
Packaging Specification:
- Single-dose vials containing 2 mg of avacincaptad pegol.
Storage:
- Store in a refrigerator at 2°C to 8°C (36°F to 46°F), protected from light.
- Unopened vials can be kept at room temperature (20°C to 25°C or 68°F to 77°F) for up to 24 hours before use.
Expiry Date:
- Refer to the packaging for the expiration date.
Executive Standard:
- Complies with relevant pharmaceutical standards for intravitreal injections.
Approval Number:
- Refer to the packaging or local regulatory authority for the approval number.
Date of Revision:
- Refer to the packaging or accompanying documentation for the date of revision.
Manufacturer:
- Iveric Bio Ophthalmology Company.

Guidelines For The Use Of Izervay

Dosage and Administration:

Recommended dose: 2 mg (0.1 mL of 20 mg/mL solution) administered via intravitreal injection.
Frequency: Once monthly (approximately every 28 ± 7 days) for up to 12 months.

Adverse Reactions:

Common adverse reactions (≥5% incidence): conjunctival hemorrhage, increased intraocular pressure, blurred vision, and neovascular (wet) AMD.

Contraindications:

Patients with ocular or periocular infections.
Patients with active intraocular inflammation.

Precautions:

Endophthalmitis and Retinal Detachment: Intravitreal injections, including Izervay, may be associated with these conditions. Employ proper aseptic injection techniques to minimize risk. Instruct patients to report any symptoms suggestive of these conditions promptly for appropriate management.
Neovascular (Wet) AMD: Increased incidence observed in clinical trials. Monitor patients receiving Izervay for signs of neovascular AMD.
Increased Intraocular Pressure (IOP): Transient increases in IOP may occur following intravitreal injections. Monitor optic nerve head perfusion and manage appropriately.

Izervay Interactions

Drug Interactions:

No specific drug interaction studies have been conducted with Izervay. Consult the prescribing information for potential interactions.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.